NCT07180511View on ClinicalTrials.gov

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

May 18, 2027

Study Completion Date

July 19, 2027

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

10mg QY201 Placebo tablet

10mg QY201 Placebo tablet

DRUG

20mg QY201 Placebo tablet

20mg QY201 Placebo tablet

DRUG

10mg QY201 tablet

10mg QY201 tablet

DRUG

20mg QY201 tablet

20mg QY201 tablet

Trial Locations (1)

Unknown

EnitiateBioPharma, Hangzhou

Sponsors
All Listed Sponsors
lead

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

INDUSTRY